tovecimig

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
tovecimig

GtoPdb Ligand ID: 14507

Synonyms: ABL001 | CTX-009 | CTX009

Compound class: Antibody

Comment: Tovecimig (CTX-009; formerly ABL001) is a bispecific monoclonal antibody that simultaneously blocks the signalling pathways that are activated by the delta-like ligand-4 (DLL4; Notch signaling) and vascular endothelial growth factor A (VEGF-A) [4]. The VEGF-A binding heavy chains of tovecimig are derived from the established anti-VEGF-A biologic bevacizumab. Two single chain variable fragments (scFv) that bind to human DLL4 are linked to the C-termini of the anti-VEGF-A heavy chains [1].

References
1. Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY et al.. (2024) COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol, 20 (30): 2241-2248. [PMID:38861293]
2. Barve MA, Boland PM, Kayali F, Mikhail S, Sachsenmeier K, Pilgrim S, Rosales MK, Pelster M. (2026) Results of a phase 2 study of a novel DLL4-VEGF, a bispecific antibody, tovecimig (CTX-009), as a monotherapy in patients with refractory metastatic colorectal cancer (COMPANION-003). J Clin Onc, 44 (2_suppl): 125. DOI: 10.1200/JCO.2026.44.2_suppl.125
3. FDA. Orphan Drug Designations and Approvals: tovecimig. Accessed on 29/04/2026. Modified on 29/04/2026. www.accessdata.fda.gov/, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1131925
4. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET et al.. (2011) DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res, 71 (18): 6073-83. [PMID:21803743]

References

1. Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY et al.. (2024)
COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.
Future Oncol, 20 (30): 2241-2248. [PMID:38861293]

2. Barve MA, Boland PM, Kayali F, Mikhail S, Sachsenmeier K, Pilgrim S, Rosales MK, Pelster M. (2026)
Results of a phase 2 study of a novel DLL4-VEGF, a bispecific antibody, tovecimig (CTX-009), as a monotherapy in patients with refractory metastatic colorectal cancer (COMPANION-003).
J Clin Onc, 44 (2_suppl): 125. DOI: 10.1200/JCO.2026.44.2_suppl.125

3. FDA.
Orphan Drug Designations and Approvals: tovecimig.
Accessed on 29/04/2026. Modified on 29/04/2026. www.accessdata.fda.gov/, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1131925

4. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET et al.. (2011)
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Cancer Res, 71 (18): 6073-83. [PMID:21803743]